Valstar (Intravesical)

Valstar (Intravesical) Uses, Dosage, Side Effects, Food Interaction and all others data.

Valstar (Intravesical) (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR. It is a semisynthetic analog of the doxorubicin, which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder.

Valstar (Intravesical) is an anticancer agent.

Valstar (Intravesical)
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Valstar (Intravesical)
Availability	Prescription only
Generic	Valrubicin
Valrubicin Other Names	Valrubicin, Valrubicina, Valrubicine, Valrubicinum
Related Drugs	bcg, Valstar, Tice BCG
Type
Formula	C₃₄H₃₆F₃NO₁₃
Weight	Average: 723.651 Monoisotopic: 723.213874712
Protein binding	>99%
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	USA
Last Updated:	September 19, 2023 at 7:00 am

Uses

Valstar (Intravesical) is an anthracycline used intravesically in the treatment of BCG-resistant bladder carcinoma.

For the treatment of cancer of the bladder.

Valstar (Intravesical) is also used to associated treatment for these conditions: In situ BCG-refractory Bladder carcinoma

How Valstar (Intravesical) works

Valstar (Intravesical) is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where after DNA intercalation, it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference with the normal DNA breaking-resealing action of DNA topoisomerase II.

Toxicity

The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms. Myelosuppression is possible if valrubicin is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder/rupture perforation). The maximum tolerated dose in humans by either intraperitoneal or intravenous administration is 600 mg/m².